Clearside Biomedical (CLSD) Stock Price, News & Analysis

Company Overview

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

Key Stats

• Today's Range: $1.03 to $1.07
• 50-Day Range: $0.99 to $1.58
• 52-Week Range: $0.92 to $2.12
• Volume: 170,553 shs
• Average Volume: 322,612 shs
• Market Capitalization: $79.63 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.33
• Consensus Rating: Buy

Clearside Biomedical Stock Analysis - MarketRank™

Clearside Biomedical scored higher than 60% of companies evaluated by MarketBeat, and ranked 449th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Clearside Biomedical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Clearside Biomedical has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Clearside Biomedical are expected to decrease in the coming year, from ($0.48) to ($0.50) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Clearside Biomedical is -2.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Clearside Biomedical is -2.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.32% of the outstanding shares of Clearside Biomedical have been sold short.

Short Interest Ratio / Days to Cover

Clearside Biomedical has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Clearside Biomedical has recently decreased by 9.74%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Clearside Biomedical does not currently pay a dividend.

Dividend Growth

Clearside Biomedical does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.32% of the outstanding shares of Clearside Biomedical have been sold short.

Short Interest Ratio / Days to Cover

Clearside Biomedical has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Clearside Biomedical has recently decreased by 9.74%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.65

News Sentiment

Clearside Biomedical has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for Clearside Biomedical this week, compared to 2 articles on an average week.

Search Interest

Only 8 people have searched for CLSD on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

Only 3 people have added Clearside Biomedical to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Clearside Biomedical insiders have bought more of their company's stock than they have sold. Specifically, they have bought $36,500.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 9.20% of the stock of Clearside Biomedical is held by insiders.

Percentage Held by Institutions

Only 18.75% of the stock of Clearside Biomedical is held by institutions.

CLSD Stock Analysis - Frequently Asked Questions

How have CLSD shares performed this year?

Clearside Biomedical's stock was trading at $1.17 at the beginning of the year. Since then, CLSD shares have decreased by 10.3% and is now trading at $1.05.
View the best growth stocks for 2024 here.

How were Clearside Biomedical's earnings last quarter?

Clearside Biomedical, Inc. (NASDAQ:CLSD) posted its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.10) EPS for the quarter, topping analysts' consensus estimates of ($0.14) by $0.04. The business earned $1.04 million during the quarter, compared to analysts' expectations of $0.25 million.

When did Clearside Biomedical IPO?

Clearside Biomedical (CLSD) raised $50 million in an initial public offering (IPO) on Thursday, June 2nd 2016. The company issued 7,200,000 shares at $7.00 per share. Cowen and Company and Stifel acted as the underwriters for the IPO and Needham & Company, Wedbush PacGrow was co-manager.

Who are Clearside Biomedical's major shareholders?

Top institutional shareholders of Clearside Biomedical include Geode Capital Management LLC (0.96%), Assenagon Asset Management S.A. (0.34%), Rosalind Advisors Inc. (0.17%) and Johnson & Johnson (0.11%). Insiders that own company stock include Bradford T Whitmore, George M Lasezkay, Charles A Deignan, Thomas Ciulla, Ngai Hang Victor Chong and Benjamin R Yerxa.
View institutional ownership trends.

How do I buy shares of Clearside Biomedical?

Shares of CLSD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Clearside Biomedical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Clearside Biomedical investors own include Northwest Biotherapeutics (NWBO), Ocular Therapeutix (OCUL), Melinta Therapeutics (MLNT), NVIDIA (NVDA), T2 Biosystems (TTOO), Advanced Micro Devices (AMD) and (ZLTQ) (ZLTQ).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 11/21/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 3/11/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CLSD
• CUSIP: N/A
• CIK: 1539029
• Web: www.clearsidebio.com
• Phone: (678) 270-3631
• Fax: 678-270-4033
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $5.33
• High Stock Price Target: $6.00
• Low Stock Price Target: $4.00
• Potential Upside/Downside: +407.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 6 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.45)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-32,490,000.00
• Net Margins: -413.83%
• Pretax Margin: -413.83%
• Return on Equity: N/A
• Return on Assets: -92.90%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.49
• Quick Ratio: 4.49

Sales & Book Value

• Annual Sales: $8.23 million
• Price / Sales: 9.68
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.25) per share
• Price / Book: -4.20

Miscellaneous

• Outstanding Shares: 75,840,000
• Free Float: 68,866,000
• Market Cap: $79.63 million
• Optionable: Optionable
• Beta: 2.33